### Guide to Contraindications and Precautions to Commonly Used Vaccines

Adapted from Table 4-1 in Advisory Committee on Immunization Practices (ACIP) General Best Practice Guidelines for Immunization: Contraindication and Precautions available at [www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html](http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html) and ACIP’s Recommendations for the Prevention and Control of 2021-22 Seasonal Influenza with Vaccines available at [www.cdc.gov/mmwr/volumes/70/rr/rr7005a1.htm](http://www.cdc.gov/mmwr/volumes/70/rr/rr7005a1.htm)

#### Interim clinical considerations for use of COVID-19 vaccines including contraindications and precautions can be found at [www.cdc.gov/vaccines/covid-19 clinical-considerations/covid-19-vaccines-us.html](http://www.cdc.gov/vaccines/covid-19 clinical-considerations/covid-19-vaccines-us.html)

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Contraindications</th>
<th>Precautions</th>
</tr>
</thead>
</table>
| Influenza, egg-based, inactivated injectable (IIV4) | • Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency)  
• Severe allergic reaction (e.g., anaphylaxis) to any vaccine component (excluding egg) | • Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine  
• Persons with egg allergy with symptoms other than hives (e.g., angioedema, respiratory distress) or required epinephrine or another emergency medical intervention: Any influenza vaccine appropriate for age and health status may be administered. If using egg-based IIV, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist.  
• Moderate or severe acute illness with or without fever |
| Influenza, cell culture-based inactivated injectable (ccIIV4), Flucelvax® Quadrivalent | • Severe allergic reaction (e.g., anaphylaxis) to any ccIIV of any valency, or to any component of ccIIV4 | • Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine  
• Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg-based IV, ccIIV, or LAIV of any valency. If using ccIIV, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist.  
• Moderate or severe acute illness with or without fever |
| Influenza, recombinant injectable (RIV4), Flublok® Quadrivalent | • Severe allergic reaction (e.g., anaphylaxis) to any RIV of any valency, or to any component of RIV4 | • Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine  
• Persons with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any egg-based IV, ccIIV, or LAIV of any valency. If using RIV, administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist.  
• Moderate or severe acute illness with or without fever |
| Influenza, live attenuated [LAIV4, Flumist® Quadrivalent] | • Severe allergic reaction (e.g., anaphylaxis) after previous dose of any influenza vaccine (i.e., any egg-based IIV, ccIIV, RIV, or LAIV of any valency)  
• Severe allergic reaction (e.g., anaphylaxis) to any vaccine component (excluding egg)  
• Adults age 50 years or older  
• Anatomic or functional asplenia  
• Immunocompromised due to any cause including, but not limited to, medications and HIV infection  
• Close contacts or caregivers of severely immunosuppressed persons who require a protected environment  
• Pregnancy  
• Cochlear implant  
• Active communication between the cerebrospinal fluid (CSF) and the oropharynx, nasopharynx, nose, ear, or any other cranial CSF leak  
• Received influenza antiviral medications oseltamivir or zanamivir within the previous 48 hours, peramivir within the previous 5 days, or baloxavir within the previous 17 days. | • Guillain-Barré syndrome (GBS) within 6 weeks after a previous dose of any type of influenza vaccine  
• Asthma in persons aged 5 years old or older  
• Persons with egg allergy with symptoms other than hives (e.g., angioedema, respiratory distress) or required epinephrine or another emergency medical intervention: Any influenza vaccine appropriate for age and health status may be administered. If using LAIV4 (which is egg based), administer in medical setting under supervision of health care provider who can recognize and manage severe allergic reactions. May consult an allergist.  
• Persons with underlying medical conditions (other than those listed under contraindications) that might predispose to complications after wild-type influenza virus infection (e.g., chronic pulmonary, cardiovascular (except isolated hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorders (including diabetes mellitus))  
• Moderate or severe acute illness with or without fever |

1. When a contraindication is present, a vaccine should NOT be administered. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization. [www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html](http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html)

2. When a precaution is present, vaccination should generally be deferred but might be indicated if the benefit of protection from the vaccine outweighs the risk for an adverse reaction. Kroger A, Bahta L, Hunter P. ACIP General Best Practice Guidelines for Immunization. [www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html](http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/contraindications.html)

3. Vaccination providers should check FDA-approved prescribing information for the most complete and updated information, including contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at [www.fda.gov/vaccines-blood-biologics/approved-products/vaccines-licensed-use-united-states](http://www.fda.gov/vaccines-blood-biologics/approved-products/vaccines-licensed-use-united-states).